Clinical Conversations in Hormone Receptor–Positive, HER2-Negative Breast Cancer
In a new and engaging five-part video roundtable from JNCCN–Journal of the National Comprehensive Cancer Network on Clinical Conversations in Breast Cancer, a distinguished faculty explore the role of CDK4/6 inhibitors in the treatment of hormone receptor–positive, HER2-negative breast cancer in the adjuvant and metastatic settings. Moderator Matthew P. Goetz, MD, is joined by Kevin Kalinsky, MD, MS, and Saranya Chumsri, MD, and they walk viewers through the various clinical considerations in therapeutic decision-making for five different patient scenarios, highlighting the clinical trial data behind such treatment options—from studies such as RxPONDER, monarchE, PALOMA-2, MONALEESA, SOFT, and TEXT.
